Not a kickback: Novartis’ Kymriah travel assistance program gets a green light from HHS

31st January 2020 Uncategorised 0

Normally, a pharma company paying a patient to take its drug looks suspicious—like a kickback—and it’s considered so under federal law. But HHS has just made a special ruling that allows Novartis to pay for travel and other out-of-pocket expenses to Medicare and Medicaid patients of its CAR-T therapy Kymriah.

More: Not a kickback: Novartis’ Kymriah travel assistance program gets a green light from HHS
Source: fierce